2.
中国肺癌免疫靶向药物研发纵览
Independent research and development of checkpoint inhibitors in China
| Category | Drug | Study progress | Approved document time |
| PD-1: programmed death 1; PD-L1: programmed death-1; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; BTLA-4: B-and T-lymphocyte attenuator-4. | |||
| PD-1 | SHR-1210 | Phase Ⅰb and phase Ⅱ study are ongoing | 2016.2 |
| BGB-A317 | Phase Ⅰ study is ongoing | 2016.9 | |
| JS001 | Phase Ⅰ study is ongoing | 2016.1 | |
| IBI308 | Phase Ⅰ study is completed | 2016.9 | |
| GLS-010 | Clinical trial application stage | 2016.4 | |
| PD-L1 | KN035 | Clinical trial application stage | 2016.4 |
| WBP3155 | Clinical trial application stage | 2016.10 | |
| JS003 | - | - | |
| CTLA-4 | KN044 | - | - |
| BTLA-4 | JS004 | - | - |